Clobetason
Generic name
Clobetason
Brand name
ATC Code
D07AB01
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Atopic dermatitis |
|---|
|
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Children are more likely to experience systemic effects.
Delayed weight gain; growth retardation.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Children are more likely to experience local and systemic side effects from the use of corticosteroids on the skin due to their larger body surface area relative to weight and generally require shorter treatment.
In infants, the diaper can act as an occlusive dressing and thus increase absorption. In children, inhibition of adrenal cortex function can occur quite quickly. In addition, the secretion of growth hormones can be suppressed in them. It is therefore recommended, if long-term application is necessary, to regularly monitor height and weight. When applied to the eyelids, careful consideration should be given to the possibility of contamination of the conjunctiva with the risk of developing glaucoma simplex or subcapsular cataract on the one hand and the risk of corneal damage from continued rubbing of untreated eczema on the other.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
CORTICOSTEROIDS, PLAIN
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Corticosteroids, weak (group I) | ||
|---|---|---|
| D07AA02 | ||
| Corticosteroids, moderately potent (group II) | ||
|---|---|---|
| D07AB02 | ||
| D07AB09 | ||
| Corticosteroids, potent (group III) | ||
|---|---|---|
| D07AC01 | ||
| D07AC03 | ||
| D07AC17 | ||
| D07AC14 | ||
| D07AC13 | ||
| D07AC18 | ||
| Corticosteroids, very potent (group IV) | ||
|---|---|---|
| D07AD01 | ||
References
- CBO, Richtlijn Constitutioneel eczeem, www.cbo.nl, Maart 2015
- NHG, Standaard Constitutioneel eczeem (M37), www.nhg.nl, augustus 2006
- Krakowski AC, et al, Management of Atopic Dermatitis in the Pediatric Population, Pediatrics, 2008, Vol. 122 No. 4, 812-824
- Dirven-Meijer PC et al, NHG standaard Eczeem, Huisarts Wet, 2014, 57(5), 240-52
Changes
Therapeutic Drug Monitoring
Overdose
